Featured

Agios Pharmaceuticals Announces PDUFA Date Extension for PYRUKYND® in Thalassemia

Agios Pharmaceuticals announced a three-month extension to the FDA's Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Ap...

Home/KnolSights/Regulatory Approvals/Agios Pharmaceuticals Announces PDUFA Date Extension for PYRUKYND® in Thalassemia